Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
暂无分享,去创建一个
M. Ahn | E. Felip | K. Emancipator | N. Rizvi | M. Hellmann | A. Patnaik | L. Gandhi | J. Eder | N. Leighl | J. Goldman | L. Horn | R. Hui | E. Garon | E. Carcereny | Jin Zhang | R. Rangwala | G. Lubiniecki | C. Roach | N B Leighl | E Felip | L Horn | K Emancipator | R Hui | E B Garon | J W Goldman | M D Hellmann | A Patnaik | L Gandhi | J P Eder | M-J Ahn | E Carcereny | R Rangwala | G M Lubiniecki | J Zhang | C Roach | N A Rizvi | J. Zhang | Joseph Paul Eder | N. B. Leighl | Reshma A. Rangwala | N. Leighl
[1] T. Aparicio,et al. PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .
[2] S. Gettinger,et al. Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[4] D. Gandara,et al. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC , 2016 .
[5] M. Dolled-Filhart,et al. Development of a Companion Diagnostic for Pembrolizumab in Non-Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. , 2016, Archives of pathology & laboratory medicine.
[6] Pembrolizumab , 2019, Reactions Weekly.
[7] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[8] David Harrington,et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.
[9] L. Sequist,et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. , 2016, The Lancet. Oncology.
[10] E. Felip,et al. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[12] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[13] J. Ahn,et al. Pembrolizumab for the treatment of non-small cell lung cancer , 2016, Expert opinion on biological therapy.
[14] P. Jänne,et al. 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) , 2015 .
[15] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[16] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[17] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[18] S. Gettinger,et al. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Dolled-Filhart,et al. Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. , 2016, Archives of pathology & laboratory medicine.
[20] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[21] M. Socinski,et al. NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC , 2016 .
[22] A. Mackensen,et al. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion , 2007, Cancer Immunology, Immunotherapy.